P ost-translational modification (PTM) of proteins is a crucial mechanism to regulate cellular processes without requiring protein synthesis de novo. Ubiquitination is one of the most versatile PTMs, and target proteins can be modified by attachment of either a single ubiquitin (Ub) molecule or chains of Ub molecules that can be linked in many different ways. In addition, ubiquitin itself can be post-translationally modified, adding yet another layer of complexity. Ubiquitination is catalyzed via an enzymatic cascade involving an E1 activating enzyme, an E2 conjugating enzyme and an E3 ubiquitin ligase. E3 ligases select the substrate and promote ubiquitin transfer onto the target either directly from the E2 conjugating enzyme, a mechanism adopted by Really Interesting New Gene (RING)-type ligases or via an E3-ubiquitin thioester intermediate as observed in homologous to E6-AP C-terminus (HECT)-type and RING-between-RING (RBR)-type ligases 1 . HECT-type E3s contain a conserved, bilobal HECT domain that recognizes the E2~Ub conjugate and forms the E3~Ub intermediate. In contrast, RBR ligases contain a tripartite domain arrangement, which consists of three zinc (Zn)-binding domains: a RING1 domain that is similar to the canonical cross-brace RING fold, followed by 'in-between-RING' (IBR) and RING2 domains that adopt highly similar structures in which the two Zn 2+ ions are coordinated in a sequential manner 2 . Substrate ubiquitination by RBR ligases is a multistep process. It starts with recognition of the E2~Ub conjugate by RING1, followed by transfer of the ubiquitin onto the catalytic cysteine in RING2 to form the thioester intermediate, and finally, transfer onto the substrate. The targeted residue can be a lysine residue in a substrate protein to monoubiquitinate or a lysine residue or the N-terminal amino group of ubiquitin to build a polyUb chain (Fig. 1 ). This process combines mechanistic features of RING and HECT-type ligases that are performed by specific subdomains of the RBR motif: the E2~Ub-recognizing RING1 and the thioester-forming RING2 domain. These domains are separated by the IBR domain and two adjacent flexible linker regions that enable the three RBR subdomains to adopt multiple conformations with respect to one another, which, together with intramolecular interactions with regions outside the RBR, allow highly variable mechanisms of inhibition and activation to occur.
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Of the 14 RBRs present in humans 3 , only Parkin, HHARI and HOIP have been studied in detail, and these are the focus of this Perspective (Box 1). Although they share commonalities in their mechanisms of action, there are also clear differences suggesting that the mechanism of ubiquitin transfer and regulation of RBRs should be regarded as a common catalytic process with many twists to accommodate specific requirements of a given system employing an RBR E3 ligase.
Inhibition
As soon as RBRs were discovered to have a catalytic cysteine, similar to the HECT-type E3 ligases 4 , it was quickly established that most RBRs restrain the enzymatic activity through inhibitory mechanisms [5] [6] [7] [8] [9] (Fig. 2a) . Notably, these modes of inhibition differ between members of the family. For example, in Parkin, the proposed E2-binding site is blocked by the small helix called repressor element of Parkin (REP), disruption of which promotes enhanced E2 binding 10 . However, blocking the E2-binding site is not a universal mechanism for regulating RBR activity, as HHARI is able to recruit UbcH7 with submicromolar affinity, even in its inhibited conformation 8 ( Fig. 2a) . Recent structures of HHARI. [11] [12] [13] and of HOIP in complex with E2 loaded with ubiquitin (E2~Ub) 14 confirm that the predicted E2-binding site on the first helix of the RING1 domain is indeed where E2 sits within these complexes ( Fig. 2b-d) . Thus, in the case of Parkin, it seems likely that some conformational rearrangements occur to expose this site in the productive Parkin-E2 complex.
In the structures of autoinhibited Parkin and HHARI, the catalytic cysteines, C431 and C357, respectively, are occluded by secondary structure elements unique to each RBR 8, 10, 15, 16 (Fig. 2a) . In the case of Parkin, this is the RING0 domain. Deletion of RING0, or point mutations in residues securing the RING0-RING2 interface, lead to increased Parkin activity, likely through enhanced access to the catalytic cysteine 10, 15, 17 . In HHARI, the catalytic cysteine is more completely occluded by a pair of charged residues in the Ariadne domain (Glu510-Arg511) 8 . In contrast, recent structures of HHARI in complex with E2~Ub show that binding of the Ub-loaded E2 is not sufficient to expose the catalytic cysteine, suggesting that further modifications are needed to release the Ariadne domain from the catalytic site 11, 13 (Fig. 2c ). The first evidence that the RBRs were regulated at the molecular level by regions outside the RBR module came from the finding that the N-terminal ubiquitin-like (Ubl) domain of Parkin maintained an inhibited conformation and that removal or disruption of this domain leads to Parkin activation 5, 18, 19 . Similarly, removal of domains N terminal to the RBR from the linear ubiquitin chain assembly complex (LUBAC) subunit HOIP leads to increased activity of HOIP 6, 7 (however, the multisubunit E3 ligase LUBAC is more complex, because HOIP has not yet been found to exist without HOIL-1 or SHARPIN, which release these autoinhibitory effects within the complex 6, 7, [20] [21] [22] ). Together, these findings suggest that domains outside the RBR module, unique to each family member, play a key role in regulating ligase activity.
activation
Elucidating how RBRs are activated is key to a mechanistic understanding of these enzymes. Parkin can be activated by binding a ubiquitin moiety that carries a phosphate group at serine 65 (phosphorylation catalyzed by the kinase PINK1) [23] [24] [25] . Activation of Parkin also requires phosphorylation of the equivalent serine in the inhibitory Ubl domain of Parkin itself (also catalyzed by PINK1) 26 . Intriguingly, in the cases of both Parkin and HHARI, structures of Parkin bound to its cognate activator phosphoubiquitin (pUb) and of HHARI bound to its cognate E2 do not seem to capture the active forms of the proteins. For example, in both structures of phosphoubiquitin-bound Parkin (one containing the C-terminal RING0-RBR and one containing the Ubl-RING0RBR), the RING0 position remains unaltered and still partially occludes the catalytic cysteine, while the REP still occludes the proposed E2-binding site 27, 28 . Similarly, when HHARI is bound to E2~Ub, the Ariadne domain still occludes the catalytic cysteine of HHARI 11, 13 ( Fig. 2c) . Therefore, it seems likely that further conformational changes are induced by other mechanisms, likely the phosphorylation of the Ubl domain in Parkin and/or by substrate binding for other RBRs, although these states are yet to be captured. Indeed, full-length NMR analysis of phosphoParkin reveals an extended, less globular conformation, but only in the presence of pUb 29 . This suggests that neither pUb nor phosphorylation of the Ubl alone is sufficient for Parkin activation, but rather, both activation mechanisms are necessary.
The role of ubiquitin and ubiquitin-like proteins. An intriguing observation from the multiple structures of RBRs now available are the apparent multiple binding sites for ubiquitin and ubiquitin-like proteins (UBL) and the potential for regulation of activity. For example, in the case of HOIP, a structure of the catalytic RING2-linear ubiquitin chain determining domain (LDD) fragment in complex with ubiquitin clearly shows separate binding sites for both acceptor and donor ubiquitin molecules 30 ( Fig. 3a) . HHARI forms additional interactions with ubiquitin via the loop linking the IBR and RING2 domains 12 . The HOIP-E2~Ub structure 14 provides details of the docking site for donor ubiquitin (Fig. 3b) , a site also predicted by the structure of a Parkin-pUb complex to bind ubiquitin 28 ( Fig. 3c ). This site is along the outside of the helix leading into the IBR domain of each protein.
Intriguingly, the opposite side of the same helix seems to mediate various regulatory interactions in the three best studied RBRs. In Parkin, it is the site of pUb binding 27, 28 . In HOIP, it is where additional ubiquitin moieties, suggested to play an allosteric role, are found in the crystal packing of the HOIP-E2~Ub structure 14 . In HHARI, this site is occupied by the UBA-like (UBA-L) domain, suggesting a potential regulation by either blocking this site or recruiting a Ubl (Fig. 3d) . Two recent structures of HHARI complexed with E2~Ub show contacts between the ubiquitin moiety and the UBA-L domain. The interaction mode, however, is different in the two structures, suggesting that multiple locations can be sampled by the E2~Ub conjugate. Finally, a recent study reports activation of Parkin by the UBL ISG15 through covalent attachment to a lysine in the immediate vicinity of the pUb-binding site 31 . . HHARI (and its homologs in other species) have been associated with a number of cellular functions including the regulation of developmental processes, protein translation and cellular proliferation 44, 55, 56 . In contrast to Parkin and HHARI, which function as single polypeptides, HOIP is a subunit of the LUBAC, a constitutive complex of two RBR-domain-containing proteins, HOIP and HOIL-1, plus SHARPIN. LUBAC was initially shown to play a crucial role in the regulation of immune and inflammatory signaling, but has since been linked to the regulation of multiple cellular functions including apoptosis and cancer [20] [21] [22] 57 .
In combination, these studies suggest a role for covalent and noncovalent ubiquitin and UBL binding in the activation and regulation of RBRs (Fig. 3e) . Furthermore, the surfaces identified to bind Ub and UBLs may constitute more general protein-protein interaction sites that could be recognized by other as-yet-unidentified regulators.
Activation by other proteins. In addition to the ubiquitin-like interactors, several other proteins influence the activity of RBR ligases. This is particularly pertinent in the case of HOIP. In contrast to Parkin and HHARI, the autoinhibited state of HOIP is constitutively released through interaction with its LUBAC partners HOIL-1 and SHARPIN. In effect, HOIP activity is regulated through association with the deubiquitinases (DUBs) OTULIN and CYLD [32] [33] [34] [35] . At present, it is not clear why this fundamental difference between the regulation of activity of LUBAC and Parkin and HHARI exists. However, there are reports of additional interacting partners stimulating activity of Parkin and HHARI. For example, interaction with Eps15 and endophilin A via the Ubl domain of Parkin point toward a possible substrate-induced relief of inhibition 5, 36, 37 . Furthermore, the Ariadne domain of HHARI binds to Cullin-RING ligases (CRLs), and this interaction greatly enhances HHARI activity 38, 39 . Finally, perturbing the intricate domain-domain associations within RBR ligases can lead to activation. For example, it is known that tagging the N terminus of Parkin with either large globular proteins or small unstructured epitope tags leads to activation, and in some cases, changes substrate preference 5, 40, 41 .
the ubiquitin transfer cycle
Over 30 ubiquitin-specific E2-conjugating enzymes exist, most of which carry out both aminolysis and transthiolation reactions and hence work with RING as well as HECT and RBR ligases 42 . In contrast, UBE2L3 (UbcH7) is strictly cysteine reactive and unable to transfer ubiquitin in conjunction with RING ligases (though curiously can form stable complexes with some of them). A number of reports suggest that UbcH7 is the physiologically relevant E2 for HOIP and HHARI 43, 44 , yet for most RBR ligases, the cognate E2(s) remain unknown, and in vitro studies often use UBE2D (UbcH5) isoforms, promiscuous E2s that are active with many different E3s.
Interaction with cognate E2 and prevention of accidental ubiquitin discharge. Isolated E2~conjugates undergo aminolysis only slowly and require a mechanism to increase the rate of ubiquitin transfer. This is achieved by complex formation with canonical RING domains that stabilize the otherwise dynamic and flexible conjugate in a closed conformation, in which the I44 hydrophobic patch of ubiquitin contacts the α 2 helix of the E2 (refs [45] [46] [47] [48] ). Given the high structural similarity of RING1 domains to canonical RINGs, this raises the question of how ubiquitin discharge onto a lysine residue is prevented upon engagement of E2~Ub conjugates (other than UbcH7) by RBR E3s. Recent structural and biochemical studies have provided an explanation for this behavior: RING1 domains stabilize an open E2~Ub conformation in which lysine reactivity is suppressed, and instead, transthiolation, an equilibrium reaction that does not require activation, is promoted 12 . Interestingly, the stabilization of an open E2~Ub conformation is observed for complexes of RBR domains with both UbcH5 and UbcH7, despite the inability of UbcH7 to transfer ubiquitin onto lysine residues. This observation indicates that the prevention of unproductive, and possibly detrimental, discharge of ubiquitin onto nearby lysine residues is a key feature determining the mode of the RING1-E2~Ub interaction. Structures of HHARI-UbcH7~Ub complexes show that the RBR-E2~Ub interaction is dominated by the RING1-E2 interface, with minor contacts between ubiquitin and the UBA-like domain of HHARI, which is located N terminal to the RBR domain 11, 13 ( Fig. 2c) . These additional contacts do not appear to be functionally important, as the isolated RING1 domain is sufficient to engage the E2~Ub in an open conformation 11 , and the presence of the UBA, IBR and RING2 domains does not increase the affinity of the E2~Ub conjugate for HHARI 49 . Recognition of UbcH7 by RING1 occurs in a similar manner to canonical E2-E3 complexes and includes residues from loops 4 and 7 of the E2 and from two Zn 2+ -coordinating loops and the central helix of HHARI RING1.The second Zn 2+ loop of most RING1 domains is longer than that in canonical RINGs 2 (by two residues in HHARI) and acts as a steric wedge to prevent UbcH7~Ub from adopting a closed conformation 11, 13 (Fig. 2c) . Furthermore, RING1 domains lack the conserved 'linchpin' , a basic residue in canonical RINGs that simultaneously contacts the E2 and ubiquitin. Interestingly, HOIP does not contain an extended Zn 2+ loop but also binds an UbcH5~Ub conjugate in the open conformation 14 (Fig. 2d) . However, in contrast to the predominantly E2-and RING1-driven HHARI-UbcH7~Ub interaction, HOIP makes extensive noncovalent contacts with ubiquitin along the entire RBR domain 14 . These contacts are crucial for complex formation, as the affinity of the HOIP RBR for isolated UbcH5 is very low, and ubiquitin conjugation is required to form a stable complex. A similar behavior is observed with HHARI, suggesting that there might be differences in the manner by which UbcH5 and UbcH7, which only transfers Ub onto cysteine, are recognized by RBRs 49 . In the case of Parkin, there is no appreciable affinity between wild-type Parkin and any E2 enzyme 18, 19 . Removal of the Ubl domain does not lead to a close association with E2s, and neither does mutation of the repressor element of Parkin. The phosphorylation of Parkin enables binding to UbcH7 with a dissociation constant of ~160 µ M
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, and addition of pUb increases the affinity ~5-fold to a K d of 20-30 µ M 18, 19, 28 . Yet, these are still low-affinity interactions, and only when the UbcH7 is loaded with ubiquitin, pUb is present, and Parkin is phosphorylated does the interaction become submicromolar 18, 28 , in the same range as the HHARI-UbcH7 interaction. The Parkin-E2~Ub complex is yet to be defined structurally, and, therefore, it is unclear what conformation will be supported by RING1 of Parkin. Moreover, in contrast to HHARI, Parkin can function with multiple E2s 5 , and, in contrast to HOIP, Parkin can catalyze the formation of multiple chain types, suggesting that there may be further layers of regulation.
Transfer of ubiquitin from E2 to RBRs. Transfer of ubiquitin from E2 to E3 requires the active site cysteines of both proteins to come into proximity. The HOIP-UbcH5~Ub complex provides a first glance at how this transthiolation step may occur 14 . The crystallized complex shows two molecules of the E2~Ub conjugate bound to two molecules of the RBR such that ubiquitin transfer would occur in trans (Fig. 2d) . However, the authors argue that this arrangement is an artifact due to a domain swap, and instead, ubiquitin transfer occurs in cis within a single RBR chain, which makes extensive contacts with ubiquitin to guide RING2 toward the E2~Ub conjugate. Intriguingly, SAXS analysis of RBR-E2~Ub complexes does not support the existence of a stable compact species in which the RBR is tightly wrapped around the E2~Ub conjugate, suggesting that this species is highly transient 49 . It is tempting to speculate that the elongated conformation of HOIP RBR observed in the crystal structure (Fig. 2b) and the domain-swapped compact conformation ( Fig. 2d ) may represent two species at opposite ends of the reaction pathway: the initial encounter complex and the E2-E3 ubiquitin transfer complex. An intriguing feature of the compact complex is the occlusion of the acceptor ubiquitin-binding site on RING2 by the bound E2 (Fig. 2d) . This could suggest that linear ubiquitin chain synthesis by HOIP is not processive, as the growing chain will need to dissociate for each round of ubiquitin transfer. The advantage of such a mechanism is not clear at present, but it may provide a regulatory mechanism to limit activity. In this respect, it is interesting that binding of ubiquitin chains to an allosteric ubiquitin-binding site formed by the IBR domain and preceding linker, opposite the donor ubiquitinbinding site, has been suggested to act as an activator, implying that linear chain synthesis might be tightly controlled by opposing positive and negative regulatory signals.
cooperation between RBR modules
LUBAC functions as at least a dimer of two RBR ligases, HOIP and HOIL-1, with an additional subunit, SHARPIN. HOIP has also been reported to function with Parkin under cellular stress, with Parkin increasing LUBAC activity 50 . In the structure of the HOIP RBR module bound to E2~Ub, the donor ubiquitin carried by the E2 bound to one molecule of HOIP interacts with the RING2 domain of a second molecule of HOIP 14 , meaning that the RING2 of one RBR completes the second RBR moiety (Fig. 2d) . It is tempting to speculate that this arrangement may mimic a potential interaction between the RBR modules of HOIP and HOIL-1, thereby adding yet another layer of regulation. Intriguingly, the crystal structure of Parkin in complex with pUb also shows a potential coupling of multiple RBR modules, whereby the IBR domain cradling the donor ubiquitin in one molecule of Parkin could transfer that ubiquitin to the RING2 domain of a second Parkin molecule 28 . Rescue experiments mixing RBR mutants lend some support to this notion. RNF144, which is an RBR ligase that contains only the RBR module and a short transmembrane domain, has been suggested to function only as a dimer, with oligomerization through the transmembrane domain, further supporting the notion that RBR domains may regulate each other 51 . However, this does not seem to be the case in HHARI 11, 13 , where transfer from E2 to E3 occurs in cis. Whether RBRs can cooperate in trans, perhaps through the multiple ubiquitin docking sites, remains an open question.
Substrate selection and chain linkage specificity
Our knowledge of the structural features underlying substrate selection by RBR ligases is currently limited to ubiquitin itself during linear chain synthesis by HOIP, which is bound by RING2 and the C-terminal LDD 30 ( Fig. 3a) . In contrast, nothing is known about how the hundreds of proposed Parkin substrates may be recognized 52 or how HHARI may select CRL substrates to prime them by monoubiquitination 39 . Substrate selection by HHARI may be driven by recognition of neddylated CRLs 38 . Linkage specificity of the polyubiquitin chain is generally believed to be determined by the last thioester-forming enzyme of the ubiquitination cascade, implying that E2 enzymes adopt this role in conjunction with RING E3s, whereas HECT and RBR ligases themselves control chain type. At present, HOIP is the only RBR member that strictly follows this rule and only synthesizes linear (M1-linked) chains. This activity requires a specific region of HOIP that binds the acceptor ubiquitin, the LDD, which is partially integrated within RING2 (Fig. 2b) . In contrast, Parkin forms multiple types of polyUb chains, whereas HHARI primarily monoubiquitinates its substrates to work with Cullin E3s, but can also mediate polyUb chain synthesis in auto-ubiquitination assays. For other RBR family members, details of linkage specificity are still largely unexplored. This apparent lack of chain linkage specificity, at least with Parkin, raises the question of why the reaction would need to proceed via an E3-thioester intermediate, which is generally assumed to provide linkage specificity.
We speculate that the multistep mechanism adopted by RBR ligases, using three domains tethered to one another by flexible linkers, may be important to allow the E3 to retain selection of the lysine residues (or the N-terminal methionine) to be modified during the initiation and chain extension process, regardless of the E2 they are working with. Furthermore, the flexible tripartite domain structure of RBRs allows multiple levels of regulation including post-translational modifications, interaction with ubiquitin, pUb, UBLs and other binding partners or association with membranes.
Future directions
At present, we only have an incomplete picture of the dynamic range of these proteins, and many questions remain unanswered, particularly with respect to substrate selection, chain linkage specificity, possible cooperation between RBR modules and regulation of activity in vivo. There are undoubtedly many more twists in the RBR tale to be uncovered!
